Clinical advances in epigenetic therapies for lymphoma

Author:

Rosenthal Allison C.,Munoz Javier L.,Villasboas J. C.

Abstract

AbstractBackgroundAdvances in understanding of cancer biology, genomics, epigenomics, and immunology have resulted in development of several therapeutic options that expand cancer care beyond traditional chemotherapy or radiotherapy, including individualized treatment strategies, novel treatments based on monotherapies or combination therapy to reduce toxicities, and implementation of strategies for overcoming resistance to anticancer therapy.ResultsThis review covers the latest applications of epigenetic therapies for treatment of B cell, T cell, and Hodgkin lymphomas, highlighting key clinical trial results with monotherapies and combination therapies from the main classes of epigenetic therapies, including inhibitors of DNA methyltransferases, protein arginine methyltransferases, enhancer of zeste homolog 2, histone deacetylases, and the bromodomain and extraterminal domain.ConclusionEpigenetic therapies are emerging as an attractive add-on to traditional chemotherapy and immunotherapy regimens. New classes of epigenetic therapies promise low toxicity and may work synergistically with other cancer treatments to overcome drug resistance mechanisms.Graphical Abstract

Publisher

Springer Science and Business Media LLC

Subject

Genetics (clinical),Developmental Biology,Genetics,Molecular Biology

Reference118 articles.

1. Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-Hodgkin's lymphoma. Med Sci. 2021;9.

2. Hodgkin lymphoma statistics. American Cancer Society Cancer Statistics Center, 2021. Available at: https://cancerstatisticscenter.cancer.org/?_ga=2.108556481.219238712.1625489148-2120540464.1618477006#!/cancer-site/Hodgkin%20lymphoma. Accessed 13 Aug 2021.

3. Survival rates and factors that affect prognosis (outlook) for non-Hodgkin lymphoma. American Cancer Society, 2022. Available at: https://www.cancer.org/cancer/non-hodgkin-lymphoma/detection-diagnosis-staging/factors-prognosis.html. Accessed 27 Jan 2023.

4. Baudino TA. Targeted cancer therapy: the next generation of cancer treatment. Curr Drug Discov Technol. 2015;12:3–20.

5. Chemotherapy side effects. National Health Service, 2020. Available at: https://www.nhs.uk/conditions/chemotherapy/side-effects/. Accessed 1 Feb 2023.

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3